# MBX Capital

> MBX Capital is a VC fund in New York backing Health Care and Biotechnology. See 59 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: New York, United States
- Total investments: 59
- Last investment: Apr 2026
- Lead investor: 7%
- Last fund: Jan 2021
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/mbx-capital
- Website: https://www.mbxcapital.com/

MBX Capital is a venture capital partnership investing in early-stage healthcare, life sciences, and environmental health companies

## Contacts

5 contacts available for MBX Capital. Shizune tracks 5 team members at MBX Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/mbx-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 30 | 51% |
| Biotechnology | 15 | 25% |
| Medical | 9 | 15% |
| Therapeutics | 5 | 8% |
| Dental | 4 | 7% |

55 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 24 | 41% |
| Seed | 16 | 27% |
| Series B | 5 | 8% |
| Funding Round | 5 | 8% |
| Pre-Seed | 1 | 2% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 42 | 71% |
| Canada | 3 | 5% |
| India | 1 | 2% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Elizabeth Burstein | Venture Partner | 0 | https://shizune.co/investors/profile/elizabeth-burnstein |
| Gurdane Bhutani | Co-founder & Managing Partner | 4 | https://shizune.co/investors/profile/gurdane-bhutani |
| Martin Gargaros | Director | 0 | https://shizune.co/investors/profile/martin-gargaros-196d |
| Puneet Sapra | Venture Partner | 0 | https://shizune.co/investors/profile/puneet-sapra |
| Zeshan Muhammedi | Co-founder & Managing Partner | 4 | https://shizune.co/investors/profile/zeshan-muhammedi |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Keebler Health | AI-Enabled Coding for Medical Billing Teams | $16M | Series A | Apr 15, 2026 |  |
| Think Bioscience | Think Bioscience is reimagining synthetic biology by guiding the design and assembly of better medicines through the use of living systems. | $55M | Series A | Jan 20, 2026 |  |
| Juniper Genomics | Juniper Genomics brings modern genomics and data science to those trying to conceive to help overcome barriers and challenges facing IVF patients. | $4.6M | Seed | Jun 26, 2025 |  |
| Vivodyne | Vivodyne develops lifelike human organs for drug testing and research purposes. The company utilizes robotic systems and artificial intelligence to create realistic human tissues that simulate various organ functions. This innovative approach allows for efficient testing of pharmaceuticals, aiming to replace traditional animal testing methods. Byproducing over 100,000 human tissues in a short timeframe, Vivodyne enhances the predictive accuracy of drug responses in humans. The organization is committed to improving the preclinical drug testing process, providing valuable insights that can lead to more effective therapies. Through its advanced technology, Vivodyne contributes to the evolution of biomedical research and development. | $40M | Series A | May 29, 2025 |  |
| CND Life Sciences | CND Life Sciences develops an accurate, evidence-based tool that helps confirm a diagnosis of synucleinopathy. CND launched the Syn-One Test, a commercially available test to detect, visualize, and quantify the presence of abnormal, phosphorylated alpha-synuclein in cutaneous nerve fibers. The test serves as an objective diagnostic tool to aid inthe confirmation of synucleinopathy in patients with suspected Parkinson’s disease (PD), dementia with Lewy body (DLB), multiple system atrophy (MSA), or pure autonomic failure (PAF).CND has research collaborations with multiple biopharmaceutical companies and is committed to advancing science in the field. | $13.5M | Series A | May 01, 2025 |  |
| Persist AI | Persist assist pharmaceutical companies in developing long-acting formulations 50% faster. Because the formulation development process is manual and relies on scientific intuition, it takes a pharmaceutical company 5-10 years to develop a long acting formulation for a drug. This effort is divided into five years of pre-clinical development and fiveyears of clinical testing. Their goal is to use machine learning and automation to reduce the time required for pre-clinical formulation development to three months, making the formulation development process 50% faster. | $12M | Series A | Mar 19, 2025 |  |
| Keebler Health | AI-Enabled Coding for Medical Billing Teams | $6M | Seed | Feb 18, 2025 |  |
| Tidal Vision | Tidal Vision is a commercial-scale manufacturer of chitosan, a non-toxic, non-hazmat, biodegradable, and market-proven industrial biopolymer extracted from crab shells. Its zero-waste chitosan extraction process produces by far the most consistent quality and lowest cost chitosan in the industry. Tidal Vision converts chitosan from different specsinto ready-to-use formulas that are optimized for industrial applications. | $140M | Series B | Feb 03, 2025 |  |
| Waypoint Bio | Optimizing cell therapy with spatial biology | $14.5M | Seed | Jun 28, 2024 |  |
| Vivodyne | Vivodyne develops lifelike human organs for drug testing and research purposes. The company utilizes robotic systems and artificial intelligence to create realistic human tissues that simulate various organ functions. This innovative approach allows for efficient testing of pharmaceuticals, aiming to replace traditional animal testing methods. Byproducing over 100,000 human tissues in a short timeframe, Vivodyne enhances the predictive accuracy of drug responses in humans. The organization is committed to improving the preclinical drug testing process, providing valuable insights that can lead to more effective therapies. Through its advanced technology, Vivodyne contributes to the evolution of biomedical research and development. | $38M | Seed | Nov 22, 2023 |  |

10 of 59 investments shown.

## Co-investors
- [Everywhere Ventures](https://shizune.co/investors/profile/everywhere-ventures) — VC Fund, 6 deals together
- [FundRx](https://shizune.co/investors/profile/fundrx) — VC Fund, 5 deals together
- [Khosla Ventures](https://shizune.co/investors/profile/khosla-ventures) — VC Fund, 5 deals together
- [Freestyle Capital](https://shizune.co/investors/profile/freestyle-capital) — VC Fund, 4 deals together
- [Gaingels](https://shizune.co/investors/profile/gaing) — VC Fund, 4 deals together
- [Village Global](https://shizune.co/investors/profile/village-global-2) — VC Fund, 4 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does MBX Capital invest in?

MBX Capital invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Seed stage. Most of the 59 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact MBX Capital?

Public channels for MBX Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at MBX Capital?

The team at MBX Capital includes Elizabeth Burstein (Venture Partner), Gurdane Bhutani (Co-founder & Managing Partner) and Martin Gargaros (Director). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co